Repatha (evolocumab) has a reassuringly clean long-term safety record. The largest and longest study to date, the FOURIER open-label extension trial, followed patients for up to 8.7 years. Rates of serious side effects, muscle problems, new-onset diabetes, bleeding strokes, and cognitive issues did not increase over time and were no higher than what was seen in patients taking a placebo.
That said, Repatha is still a relatively newer medication, and it’s reasonable to want a detailed breakdown of what the evidence actually shows for each concern.
What the Longest Studies Tell Us
The best long-term data comes from the FOURIER trial and its extension study, published in Circulation. Patients who started Repatha at the beginning of the original trial were tracked for a median of 7.1 years, with some followed for as long as 8.7 years. That’s a substantial window to detect problems that might emerge slowly.
The key finding: none of the side effects that researchers were specifically watching for (serious adverse events, muscle-related events, new-onset diabetes, hemorrhagic stroke, and neurocognitive events) occurred at higher rates in the Repatha group compared to placebo. Crucially, these rates also didn’t creep upward over the years, which would have been a red flag for cumulative harm. Instead, the long-term users continued to see cardiovascular benefits, with a 23% lower risk of cardiovascular death and a 20% lower risk of heart attack or stroke compared to those who started on placebo.
Memory and Cognitive Function
One of the most common worries about Repatha is whether drastically lowering LDL cholesterol could harm the brain. Cholesterol plays a role in nerve cell membranes, so the concern isn’t unreasonable. Researchers took it seriously enough to design a dedicated study called EBBINGHAUS, which gave 1,204 patients computerized tests measuring memory and executive function at regular intervals.
After an average of 19 months, there was no difference in cognitive performance between the Repatha and placebo groups. A larger patient-reported survey of over 22,600 people backed this up: after a median of 2.2 years, the proportion reporting cognitive decline was nearly identical (3.7% on Repatha versus 3.6% on placebo). Even among patients whose LDL cholesterol dropped to extremely low levels (below 20 mg/dL), self-reported cognitive decline was no more common than in patients with LDL levels above 100 mg/dL (3.8% versus 4.5%, a difference that was not statistically meaningful).
Diabetes Risk
Statins, the most widely prescribed cholesterol-lowering drugs, carry a small but real increase in diabetes risk. This naturally raises the question of whether Repatha, which lowers LDL through a completely different mechanism, does the same.
So far, the answer is no. The FOURIER trial found no significant difference in new-onset diabetes between Repatha and placebo over 2.2 years. In the longest-running extension study (the OSLER-1 trial, which tracked patients for up to 4 years), the annual rate of new diabetes was actually lower in the Repatha group: 2.8% per year compared to 4.0% in the control group. Repatha works by blocking a protein called PCSK9, which operates differently from the pathway statins use, and the data so far suggests it doesn’t carry the same metabolic tradeoff.
Muscle Pain and Joint Symptoms
Muscle aches are one of the most common reasons people stop taking statins, so it’s worth knowing whether adding Repatha compounds that problem. In the FOURIER extension study, muscle-related events in the Repatha group did not exceed rates seen with placebo and did not increase over the full follow-up period. For people who switched to Repatha specifically because they couldn’t tolerate statins, this is particularly relevant: the drug doesn’t appear to trigger the same kind of muscle complaints.
Injection Site Reactions and Allergic Responses
Because Repatha is an injected medication (given every two weeks or once monthly), some people experience mild redness, bruising, or soreness at the injection site. These reactions are typically minor and tend to decrease over time rather than worsen.
The more serious concern is hypersensitivity. The FDA’s current prescribing information includes a warning about allergic reactions, including a rare but potentially severe form called angioedema (swelling of the face, lips, or throat). If you experience signs of a serious allergic reaction, you should stop taking Repatha. It’s also worth noting that certain versions of the autoinjector and prefilled syringe contain a latex derivative in the needle cover, which matters if you have a latex allergy. Latex-free versions are available.
Concerns That Haven’t Materialized
When Repatha first gained approval, several theoretical risks were on researchers’ radar. Very low LDL cholesterol was hypothesized to potentially increase the risk of hemorrhagic stroke (the type caused by bleeding rather than a clot), since cholesterol is a component of blood vessel walls. The FOURIER extension data showed no increase in hemorrhagic stroke rates. Similarly, there was speculation about possible links to cataracts or other eye problems, liver damage, and hormonal disruptions. None of these have emerged as real signals across years of monitoring thousands of patients.
The overall picture after nearly a decade of data is that Repatha’s side effect profile stays stable over time. The risks that exist, primarily injection site reactions and rare allergic responses, are apparent early on rather than building up with prolonged use. For a drug designed to be taken indefinitely, that’s a meaningful finding.